<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825914</url>
  </required_header>
  <id_info>
    <org_study_id>CAGLUCIM2016</org_study_id>
    <nct_id>NCT02825914</nct_id>
  </id_info>
  <brief_title>CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)</brief_title>
  <acronym>CAGLUCIM</acronym>
  <official_title>CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent
      colitis and using human in vitro inflammation models. Its use as a food ingredient has proven
      safe and with no influence on dietary intake. In a pilot study the investigators found, that
      orally administered CGMP seems to have a beneficial effect comparable to that of mesalazine
      in active distal ulcerative colitis.

      The investigators wish to evaluate the effects in a larger group of patients with active
      ulcerative colitis by studying the clinical effects and assessing the anti-inflammatory and
      microbiome modulating properties.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients in endoscopic remission/macroscopic mucosal healing (Endoscopic Mayo Score of 0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients in clinical remission (SCCAI ≤ 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients with clinical response (reduction of SCCAI-score of at least 2 points)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal inflammatory marker</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients with a fecal-calprotectin below 150 mg/kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic response</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients with endoscopic response (reduction of Endoscopic Mayo Score of at least 1point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid-free remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients in steroid-free remission (SCCAI ≤ 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission at follow-up</measure>
    <time_frame>26 weeks</time_frame>
    <description>The number of patients in clinical remission (SCCAI ≤ 2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Casein glycomacropeptide (CGMP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of CGMP-protein-shake during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of placebo-shake consisting of milk powder during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Casein glycomacropeptide (CGMP)</intervention_name>
    <arm_group_label>Casein glycomacropeptide (CGMP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ulcerative colitis (verified by mucosal histology and endoscopy)

          -  Clinically active ulcerative colitis (SCCAI ≥ 3)

        Exclusion Criteria:

          -  Endoscopically inactive disease (Endoscopic Mayo Score of 0)

          -  Lactose or milk protein intolerance

          -  Celiac disease

          -  Not able to understand or speak Danish.

          -  Pregnant or nursing.

          -  Growth of pathogenic bacteria in stool culture from 4 weeks before and until
             randomization (Salmonella, Campylobacter, Yersinia or Clostridium Difficile.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik A Vilstrup, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pernille G Wernlund, MD</last_name>
    <email>pernillewernlund@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of medicine V (Hepatology and Gastroenterology)</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pernille G Wernlund, MD</last_name>
      <email>pernillewernlund@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glycopeptides</keyword>
  <keyword>human microbiome</keyword>
  <keyword>caseinomacropeptide</keyword>
  <keyword>whey protein</keyword>
  <keyword>dietary proteins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Caseins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

